Journal article
Lung cancer
AA Thai, BJ Solomon, LV Sequist, JF Gainor, RS Heist
Lancet | Published : 2021
Abstract
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial improvements in our understanding of disease biology, application of predictive biomarkers, and refinements in treatment have led to remarkable progress in the past two decades and transformed outcomes for many patients. This seminar provides an overview of advances in the screening, diagnosis, and treatment of non-small-cell lung cancer and small-cell lung cancer, with a particular focus on targeted therapies and immune checkpoint inhibitors.
Grants
Awarded by American Association for Cancer Research
Funding Acknowledgements
This research was supported by a Stand Up To Cancer (SU2C), American Cancer Society Lung Cancer Dream Team Translational Research Grant (grant: SU2C-AACR-DT17-15). SU2C is a programme of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, a scientific partner of SU2C. The Massachusetts General Hospital (MGH) Targeting a Cure Fund helped support the graphics work. We sincerely thank Dr Anna Farago (MGH, Boston, MA, USA) and Dr Alice Shaw (MGH, Boston, MA, USA) for their contributions during the initial design and construction of the seminar, and Dr David Ball (Peter MacCallum Cancer Centre, Melbourne, VIC, Australia) and Dr Gavin Wright (Peter MacCallum Cancer Centre, Melbourne, VIC, Australia) for their critical review of the manuscript.